Approximately 30% of AML patients harbor FMS-like tyrosine kinase 3 (FLT3) mutations, which are associated with high blast counts, low complete remission (CR) rates, reduced disease-free survival and overall survival (OS) (4, 5). The gene discussed is FLT3; the disease is acute myeloid leukemia.